An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective
in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults. Medications that
increase dopamine are often effective in treating ADHD in adults. Since naltrexone is a kappa
opioid receptor antagonist, it increases dopamine in the brain.
We predict that naltrexone as a monotherapy will be effective for ADHD symptoms in adults
with ADHD.